Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19.

Kara W ChewCarlee MoserEric S DaarDavid A WohlJonathan Z LiRobert CoombsJustin RitzMark GigantiArzhang Cyrus JavanYijia LiCarlos MalvestuttoPaul KlekotkaKaren PriceAjay NirulaWilliam FischerVeenu BalaRuy M RibeiroAlan S PerelsonCourtney V FletcherJoseph J EronJudith S CurrierMichael D HughesDavey M Smith

Published in: medRxiv : the preprint server for health sciences (2021)

Nasal virus shedding was not associated with symptoms or baseline risk factors for severe COVID-19. Bamlanivimab, which has been associated with reduced hospitalizations in high-risk individuals, demonstrated antiviral activity with early post-treatment NP sampling but did not accelerate symptom improvement. The clinical utility of bamlanivimab for outcomes other than hospitalizations and deaths, including longer-term outcomes, is uncertain.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
early onset
depressive symptoms
skeletal muscle
combination therapy
metabolic syndrome
drug induced
preterm birth